Archive: 2025/12

Tentative Approval for Generics: Common Reasons for Delays

Posted by Paul Fletcher
1 Comments

Tentative Approval for Generics: Common Reasons for Delays

Tentative FDA approval for generics means the drug is scientifically ready - but legal, manufacturing, or economic barriers often block its market launch. Here's why so many generics never reach patients.

read more
Drug Safety Monitoring: How the FDA Tracks Generic Drugs After Approval

Posted by Paul Fletcher
0 Comments

Drug Safety Monitoring: How the FDA Tracks Generic Drugs After Approval

The FDA doesn't stop monitoring generic drugs after approval. Using real-time data, inspections, and patient reports, it tracks safety issues long after these affordable medications hit the market. Here's how it works.

read more
Immunotherapy: How Checkpoint Inhibitors and CAR-T Cell Therapy Are Changing Cancer Treatment

Posted by Paul Fletcher
0 Comments

Immunotherapy: How Checkpoint Inhibitors and CAR-T Cell Therapy Are Changing Cancer Treatment

Checkpoint inhibitors and CAR-T cell therapy are transforming cancer treatment by harnessing the immune system. Learn how they work, who benefits most, their side effects, and why access remains unequal.

read more